MiSight, first contact lens indicated to slow the progression of nearsightedness in children
The U.S. Food and Drug Administration has approved the first contact lens indicated to slow the progression of myopia (nearsightedness)
Thanks to our close relationship with vendors and manufacturers, we have the unique capability to find niche products and hard to find medicines. You can rely on us for getting the newest approved products in the market and those not yet available in some countries. Our range of products is so wide, you won’t need to look for other suppliers.
with a wide clients’ base made of hospitals, private clinics, pharmacies and distributors, we have developed a deep knowledge of what the needs, constraints and priorities are for each or our client. That is why we understand your urgency and we can fully meet your demands with the highest standards of service.
Our stringent operating procedures guarantee every step of handling, storage and distribution of all medicinal products.
When you contact us in Elixi, you know you are getting the best customer service: our dedicated people will offer you quick responses, personalised approach and bespoke solutions. Our approach is not to follow only standard procedures but taking care of every specific detail and taking to heart every request and individual issues.
The U.S. Food and Drug Administration has approved the first contact lens indicated to slow the progression of myopia (nearsightedness)
The U.S. Food and Drug Administration has approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults
EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Ervebo (rVSVΔG-ZEBOV-GP), the first vaccine
EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Baqsimi (glucagon), the first treatment for
The U.S. Food and Drug Administration has approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine
The U.S. Food and Drug Administration has approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with
Vicolo Oldelli 1
6830 Chiasso / Switzerland
Email info@elixi-int.com
Phone/Fax +41 91 6822040